BOLT
Income statement / Annual
Last year (2023), Bolt Biotherapeutics, Inc.'s total revenue was $7.88 M,
an increase of 37.48% from the previous year.
In 2023, Bolt Biotherapeutics, Inc.'s net income was -$69.20 M.
See Bolt Biotherapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$7.88 M
|
$5.73 M
|
$1.26 M
|
$231,000.00
|
$215,000.00
|
$0.00
|
| Cost of Revenue |
$61.54 M |
$4.89 M |
$3.67 M |
$40.36 M |
$26.00 M |
$302,000.00 |
| Gross Profit |
-$53.67 M |
$838,000.00 |
-$2.41 M |
-$40.13 M |
-$25.79 M |
-$302,000.00 |
| Gross Profit Ratio |
-6.81 |
0.15 |
-1.91 |
-173.71 |
-119.94 |
0 |
| Research and Development
Expenses |
$61.54 M
|
$73.12 M
|
$75.66 M
|
$40.36 M
|
$26.00 M
|
$9.42 M
|
| General & Administrative
Expenses |
$22.53 M
|
$22.93 M
|
$18.39 M
|
$9.06 M
|
$5.18 M
|
$2.21 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$22.53 M
|
$22.93 M
|
$18.39 M
|
$9.06 M
|
$5.18 M
|
$2.21 M
|
| Other Expenses |
$0.00 |
$0.00 |
-$6.08 M |
-$11.75 M |
-$42,000.00 |
-$153,000.00 |
| Operating Expenses |
$84.07 M |
$96.05 M |
$94.05 M |
$49.41 M |
$31.18 M |
$11.63 M |
| Cost And Expenses |
$84.07 M |
$96.05 M |
$94.05 M |
$49.41 M |
$31.18 M |
$11.63 M |
| Interest Income |
$7.00 M |
$2.22 M |
$281,000.00 |
$199,000.00 |
$524,000.00 |
$193,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.85 M
|
$4.89 M
|
$3.67 M
|
$2.50 M
|
$1.33 M
|
$302,000.00
|
| EBITDA |
-$74.34 M
|
-$88.66 M
|
-$91.60 M
|
-$48.57 M
|
-$30.63 M
|
-$11.33 M
|
| EBITDA Ratio |
-9.44 |
-15.47 |
-67.87 |
-159.42 |
-142.29 |
0 |
| Operating Income Ratio
|
-9.67
|
-15.77
|
-73.64
|
-212.91
|
-144.04
|
0
|
| Total Other
Income/Expenses Net |
$7.00 M
|
$2.22 M
|
-$5.80 M
|
-$11.55 M
|
$482,000.00
|
$40,000.00
|
| Income Before Tax |
-$69.20 M |
-$88.10 M |
-$98.59 M |
-$60.73 M |
-$30.49 M |
-$11.59 M |
| Income Before Tax Ratio
|
-8.79
|
-15.38
|
-78.25
|
-262.89
|
-141.8
|
0
|
| Income Tax Expense |
$0.00 |
-$2.22 M |
$5.80 M |
$11.55 M |
-$482,000.00 |
$40,000.00 |
| Net Income |
-$69.20 M |
-$85.88 M |
-$104.39 M |
-$72.27 M |
-$30.01 M |
-$11.59 M |
| Net Income Ratio |
-8.79 |
-14.99 |
-82.85 |
-312.87 |
-139.56 |
0 |
| EPS |
-1.83 |
-2.3 |
-2.79 |
-1.99 |
-0.85 |
-1.23 |
| EPS Diluted |
-1.83 |
-2.3 |
-2.79 |
-1.99 |
-0.85 |
-1.23 |
| Weighted Average Shares
Out |
$37.81 M
|
$37.36 M
|
$37.40 M
|
$36.25 M
|
$35.10 M
|
$9.42 M
|
| Weighted Average Shares
Out Diluted |
$37.81 M
|
$37.36 M
|
$37.40 M
|
$36.25 M
|
$35.10 M
|
$9.42 M
|
| Link |
|
|
|
|
|
|
